Cargando…

Characterization of β-adrenergic receptors in bovine intramuscular and subcutaneous adipose tissue: comparison of lubabegron fumarate with β-adrenergic receptor agonists and antagonists

Chinese hamster ovary cell constructs expressing either the β (1)-, β (2)- or β (3)-adrenergic receptor (AR) were used to determine whether a novel β-AR modulator, lubabegron fumarate (LUB; Experior, Elanco Animal Health) might exert greater potency for a specific β-AR subtype. EC(50) values calcula...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Jinhee H, Spurlock, Michael E, Kube, John C, Li, Xiang Z, Smith, Stephen B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326056/
https://www.ncbi.nlm.nih.gov/pubmed/34337647
http://dx.doi.org/10.1093/jas/skab116
Descripción
Sumario:Chinese hamster ovary cell constructs expressing either the β (1)-, β (2)- or β (3)-adrenergic receptor (AR) were used to determine whether a novel β-AR modulator, lubabegron fumarate (LUB; Experior, Elanco Animal Health) might exert greater potency for a specific β-AR subtype. EC(50) values calculated based on cAMP accumulation in dose response curves indicate that LUB is highly selective for the β (3)-AR subtype, with an EC(50) of 6 × 10(–9) M, with no detectible agonistic activity at the β (2)-AR. We hypothesized that the accumulation of lipolytic markers would reflect the agonist activity at each of the β-receptor subtypes of the specific ligand; additionally, there would be differences in receptor subtype expression in subcutaneous (s.c.) and intrmuscular (i.m.) adipose tissues. Total RNA was extracted from adipose tissue samples and relative mRNA levels for β (1)-, β(2)-, and β (3)-AR were measured using real-time quantitative polymerase chain reaction. Fresh s.c. and i.m. adipose tissue explants were incubated with isoproterenol hydrochloride (ISO; β-AR pan-agonist), dobutamine hydrochloride (DOB; specific β (1)-AA), salbutamol sulfate (SAL; specific β (2)-AA), ractopamine hydrochloride (RAC), zilpaterol hydrochloride (ZIL), BRL-37344 (specific β (3)-agonist), or LUB for 30 min following preincubation with theophylline (inhibitor of phosphodiesterase). Relative mRNA amounts for β (1)-, β (2)-, and β (3)-AR were greater (P < 0.05) in s.c. than in i.m. adipose tissue. The most abundant β-AR mRNA in both adipose tissues was the β (2)-AR (P < 0.05), with the β (1)- and β (3)-AR subtypes being minimally expressed in i.m. adipose tissue. ISO, RH, and ZH stimulated the release of glycerol and nonesterified fatty acid (NEFA) from s.c. adipose tissue, but these β-AR ligands did not alter concentrations of these lipolytic markers in i.m. adipose tissue. LUB did not affect glycerol or NEFA concentrations in s.c. or i.m. adipose tissue, but attenuated (P < 0.05) the accumulation of cAMP mediated by the β (1)- and β (2)-AR ligands DOB and SAL in s.c. adipose tissue. Collectively, these data indicate that bovine i.m. adipose tissue is less responsive than s.c. adipose tissue to β-adrenergic ligands, especially those that are agonists at the β (1)- and β(3)-receptor subtypes. The minimal mRNA expression of the β (1)- and β (3) subtypes in i.m. adipose tissue likely limits the response potential to agonists for these β-AR subtypes.